$122.71
N/A
À la clôture: Nov 13, 4:00 PM EST
Haemonetics rose 66.0% from $73.91 to $122.71, ahead of the S&P 500's +12.7%. Its worst day was Feb 6 (−8.7%), and its low came May 11 at $52.24.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $1.31 beat the $1.26 estimate on $339.0M revenue (est. $333.3M); FY revenue guidance of $1.3B–$1.3B against the $1.3B consensus.
−1.4% · S&P 500 −1.2%
Story events cover the past 12 months · Times ET
EPS of $1.29 beat the $1.27 estimate on $346.4M revenue (est. $337.1M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
+3.2% · S&P 500 −0.3%
Haemonetics shares rose 6.5%, while the S&P 500 rose 0.1%.
+6.5% · S&P 500 +0.1%
EPS of $1.14 beat the $1.09 estimate on $339.4M revenue (est. $329.2M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
+1.7% · S&P 500 −0.2%
Haemonetics anticipates CSL to transition a portion of its U.S.
+15.9% · S&P 500 −0.7%
Haemonetics shares rose 17.5%, while the S&P 500 fell 0.4%.
+17.5%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $1.35 beat the $1.29 estimate on $357.8M revenue (est. $345.5M); FY revenue guidance of $1.4B–$1.5B against the $1.4B consensus.
−2.6% · S&P 500 −4.4%
Where it ended: a close of $122.71 on Nov 12, 2026. Up next: Q3 2027 earnings on Feb 4, 2027 (EPS est. $1.27, revenue est. $357.6M).
Nothing in the past 12 months.
All HAE dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HAE and SPY from Benzinga historical bars. Not investment advice.